Guam parkinsonism--dementia complex (G-PDC) is an enigmatic neurodegenerative disease that affects the Chamorro residents of the Pacific island of Guam. G-PDC is clinically characterized by progressive cognitive impairment with extrapyramidal signs. Pronounced loss of neurons and abundant neurofibrillary tangles (NFTs) are observed throughout the brain of G-PDC patients \[[@CR6], [@CR7]\]. Although several hypotheses have been suggested for the cause of G-PDC, notably genetic predisposition and exposure to neurotoxins (e.g., β-*N*-methylamino-L-alanine (BMAA)), the etiology and pathogenesis remain elusive \[[@CR10]\].

A frameshift mutant of ubiquitin, known as ubiquitin-B^+1^ (UBB^+1^), was previously found to accumulate in the neuropathological hallmarks of Alzheimer's disease and several other disorders, including tauopathies and polyglutamine diseases \[[@CR1], [@CR3], [@CR12]\] (Fig. [1a-b](#Fig1){ref-type="fig"}). UBB^+1^ is a dose-dependent inhibitor of the ubiquitin-proteasome system (UPS) and its accumulation in cells an indicator of protein quality control failure. Impaired protein homeostasis is a frequent feature of neurodegenerative diseases and we hypothesized that accumulation of UBB^+1^ might also be observed in G-PDC. To test whether UBB^+1^ is detectable in G-PDC brains, immunohistochemical analyses were performed on G-PDC post-mortem brain tissue (Table [1](#Tab1){ref-type="table"}). Immunohistochemistry confirmed the presence of numerous NFTs in G-PDC brains \[[@CR5]\] (not shown), as well as other pathology that has been described to occur in G-PDC, i.e., TAR DNA-binding protein 43 (TDP-43)-positive inclusions \[[@CR5]\] (Fig. [1f-h](#Fig1){ref-type="fig"}). Importantly, our results show that UBB^+1^ is present in G-PDC brains. UBB^+1^ deposits were found specifically in cytoplasm of pyramidal neurons and glia (astrocytes in the alveus and stratum oriens) in Ammon's horn, showing a granular and tangle-like pattern of distribution (Fig. [1c-e](#Fig1){ref-type="fig"}). UBB^+1^ was not detected in young control brains (*n* = 2, non-Guamanian cases, ages: 52 and 59 years old) \[[@CR8]\]. Aggregate structures containing distinct components of the UPS, i.e., the deubiquitinating enzyme (DUB) ubiquitin C-terminal hydrolase L1 (UCH-L1) \[[@CR9]\] (Fig. [1i-k](#Fig1){ref-type="fig"}) and the proteasomal ATPase subunit Rpt3/S6b \[[@CR13]\] (Fig. [1l-n](#Fig1){ref-type="fig"}), were also present in these brains.Fig. 1Mutant ubiquitin (UBB^+1^) is deposited in Guam parkinsonism--dementia complex (G-PDC) brains. **a** UBB^+1^ is generated through "molecular misreading", a type of transcriptional mutagenesis. The resulting unfaithful RNA messengers can generate abnormal proteins with cytotoxic properties. **b** UBB^+1^ contains an extended C-terminal domain, which can be recognized by anti-UBB^+1^ antibodies. Deubiquitating enzymes (DUBs) can hydrolyze this extended C-terminus. However, inhibition of these DUBs, e.g., by oxidative stress conditions, prevents this cleavage, preserving the epitope \[[@CR2]\]. **c-e** Immunostaining for UBB^+1^ (Ubi2A, 1:400, Dr. F.W. van Leeuwen \[[@CR3]\]) reveals many cytoplasmic structures in neurons and glial cells (i.e., astrocytes in the alveus and stratum oriens) of the hippocampus. **f-h** Additionally, cytoplasmic TAR DNA-binding protein 43 (TDP-43) aggregates can be observed in the same cell types (mouse anti-TDP-43, 1:1000, Abnova). **i-k** Aggregates containing ubiquitin C-terminal hydrolase L1 (UCH-L1) (rabbit anti-UCH-L1, 1:500, Biomol), a DUB, and **l-n** Rpt3/S6b (rabbit anti-Rpt3, 1:400, Biomol), a proteasomal subunit \[[@CR13]\], are also found in G-PDC. Several immunoreactive structures show a granular staining pattern (arrowheads). All immunostainings were carried out on 6 μm thick formalin-fixed, paraffin-embedded sections. Panels **c-n** all show representative images of G-PDC hippocampi (adjacent sections from subject \#2, Table [1](#Tab1){ref-type="table"}). *Scale bars* 200 μm (**c, f, i, l**), 100 μm (**d, g, j, m**), and 50 μm (**e, h, k, n**) Table 1Description of the subjectsSubjectSexAge of death (years)Age of onset (years)Disease duration (months)Brain weight (g)Post-mortem delayCause of deathUBB^+1^1F51421168503 hperforated gastric ulcer++2M64587212757 hpulmonary atelectasis++++3M524212610254 hbronchopneumonia++4M56461261235\< 10 hbronchopneumonia+++5F51465911358 hbronchopneumonia++6M848050110014 hbronchopneumonia++

This demonstration of UBB^+1^-immunoreactivity and accumulation of particular UPS components in G-PDC brains (*n* = 6) might have important implications for understanding of the pathological mechanisms underlying the disease. UBB^+1^ has previously been shown to induce neuronal defects in in vitro and in vivo experimental models: long-term UPS inhibition due to UBB^+1^ expression causes memory deficits and central breathing dysfunction in mice \[[@CR4], [@CR8], [@CR11]\]. In addition, UBB^+1^ might act as a modifier of other pathology in G-PDC. For example, UBB^+1^ may enhance the aggregation and cellular toxicity of the RNA-binding protein TDP-43 through interfering with its degradation. It is striking that UBB^+1^ accumulates in glial cells in G-PDC, because similar glial inclusions have been reported in progressive supranuclear palsy (PSP) \[[@CR3]\], a disease that displays some similar topography of neurofibrillary degeneration \[[@CR10]\]. Recognition of common mechanistic themes shared by neurodegenerative disorders, such as dysfunctional (ubiquitin-dependent) protein degradation and proteotoxic stress, may help in identifying therapeutic targets that prevent neurodegeneration. It will be interesting to investigate the potential contribution of disrupted proteostasis and UBB^+1^ to G-PDC in more detail in future studies.
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